Exciting news! Our client, Dewpoint Therapeutics, has been recognized as “One to Watch” by The Pharma Letter.

Written By Kimberly Hicks
Kimberly Hicks
Previous

Dewpoint Therapeutics succeeds in the nomination of DPTX3496 as their second development candidate!
Next

Our client, Alnylam Pharmaceuticals submits a sNDA to the FDA